From Surf Wiki (app.surf) — the open knowledge base
Fluorodopa (18F)
Chemical compound
Chemical compound
| Field | Value | ||||
|---|---|---|---|---|---|
| drug_name | Fluorodopa () | ||||
| image | Fluorodopa F-18.svg | ||||
| image_class | skin-invert-image | ||||
| tradename | Fluorodopa F18 | ||||
| Drugs.com | |||||
| DailyMedID | Fluorodopa | ||||
| pregnancy_AU | |||||
| routes_of_administration | Intravenous | ||||
| ATC_prefix | V09 | ||||
| ATC_suffix | IX05 | ||||
| legal_AU | |||||
| legal_BR | |||||
| legal_CA | |||||
| legal_DE | |||||
| legal_NZ | |||||
| legal_UK | |||||
| legal_US | Rx-only | ||||
| legal_US_comment | |||||
| legal_UN | |||||
| legal_status | |||||
| CAS_number | 92812-82-3 | ||||
| PubChem | 56494 | ||||
| DrugBank | DB13848 | ||||
| ChemSpiderID | 50970 | ||||
| UNII | 2C598205QX | ||||
| KEGG | D04220 | ||||
| ChEBI | 49166 | ||||
| ChEMBL | 3400972 | ||||
| synonyms | 6-fluoro-L-DOPA, FDOPA | ||||
| IUPAC_name | (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid | ||||
| C | 9 | H=10 | F=1 | N=1 | O=4 |
| SMILES | C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N | ||||
| StdInChI | 1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1 | ||||
| StdInChIKey | PAXWQORCRCBOCU-RPDRGXCHSA-N |
| Drugs.com =
| elimination_half-life =
Fluorodopa (18F), also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).
The most common side effects are injection site pain.
Medical uses
Fluorodopa (18F) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes.
History
In October 2019, Fluorodopa (18F) was approved in the United States for the visual detection of certain nerve cells in adults with suspected Parkinsonian syndromes.
The US Food and Drug Administration approved Fluorodopa F 18 based on evidence from one clinical trial of 56 participants with suspected Parkinsonian syndromes. The trial was conducted at one clinical site in the United States.
References
References
- (June 2002). "Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA". Tetrahedron: Asymmetry.
- (12 October 2019). "Fluorodopa F18 injection".
- (27 November 2019). "Drug Trials Snapshots: Fluorodopa F 18".
- (20 November 2019). "Drug Approval Package: Fluorodopa F18".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Fluorodopa (18F) — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report